Skip to main content
Medexus Pharmaceuticals Inc. logo

Medexus Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · MDP ISIN · CA58410Q2036 LEI · 8945002TBEYY0HLH1M19 TSX Manufacturing
Open in API
Filings indexed 638 across all filing types
Latest filing 2021-09-22 Capital/Financing Update
Country CA Canada
Listing TSX MDP

About Medexus Pharmaceuticals Inc.

https://www.medexus.com/en_US

Medexus Pharmaceuticals, Inc. is an innovative specialty pharmaceutical company engaged in the development and commercialization of treatment solutions. The company utilizes a highly scalable North American business model, leveraging a fully integrated infrastructure encompassing commercial operations, supply chain, regulatory affairs, and a dedicated salesforce. Medexus focuses on building a portfolio of specialty and rare disease products across key therapeutic areas, including hematology, hematology-oncology, allergy, dermatology, and rheumatology. Its mission is to deliver quality healthcare products to patients and healthcare professionals.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the expanded commercial availability of a pharmaceutical product (Trecondyv) in Canada, along with details about an interest payment on convertible debentures being satisfied by issuing common shares. It includes forward-looking statements and contact information for investor relations. There are no detailed financial statements, quarterly or annual results, nor is it a transcript of a call or a regulatory filing like an audit or governance report. The content focuses on a capital/financing update (interest payment in shares) and commercial product availability, which fits best under Capital/Financing Update (CAP). The document length is 9039 characters, sufficient for a substantive announcement rather than a brief notice. Therefore, the classification is CAP with high confidence.
2021-09-22 English
Report of voting results.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'REPORT OF VOTING RESULTS' from the Annual and Special Meeting of Shareholders of Medexus Pharmaceuticals Inc. It details the voting outcomes on various shareholder matters including election of directors, re-appointment of auditors, approval of by-law amendments, and equity incentive plan changes. The content focuses exclusively on the official results of shareholder votes at a general meeting, with percentages of votes for and against each item. There is no financial data, management discussion, or presentation material. The document length is 3017 characters, which is relatively short and consistent with a voting results announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2021-09-16 English
News release - English.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a press release announcing the results of the annual and special meeting of shareholders, including the election of the board of directors and voting outcomes on other matters such as auditor re-appointment and by-law amendments. It provides detailed voting results for director elections, which is characteristic of a Declaration of Voting Results & Voting Rights Announcements document. The document is relatively short (3239 characters) and focuses on voting results rather than the full AGM materials or annual report. Therefore, it fits best under the category for Declaration of Voting Results & Voting Rights Announcements (DVA).
2021-09-16 English
News release - English.pdf
Regulatory Filings
2021-09-02 English
Management information circular - English.pdf
Regulatory Filings
2021-08-17 English
Form of proxy - French.pdf
Regulatory Filings
2021-08-17 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.